Xilio Therapeutics Statistics
Total Valuation
XLO has a market cap or net worth of $36.28 million. The enterprise value is -$77.70 million.
Important Dates
The last earnings date was Thursday, August 14, 2025, before market open.
| Earnings Date | Aug 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
XLO has 51.83 million shares outstanding. The number of shares has increased by 17.92% in one year.
| Current Share Class | 51.83M |
| Shares Outstanding | 51.83M |
| Shares Change (YoY) | +17.92% |
| Shares Change (QoQ) | -30.62% |
| Owned by Insiders (%) | 14.26% |
| Owned by Institutions (%) | 16.74% |
| Float | 23.43M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.42 |
| Forward PS | 0.88 |
| PB Ratio | 5.13 |
| P/TBV Ratio | 5.13 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.32, with a Debt / Equity ratio of 1.07.
| Current Ratio | 2.32 |
| Quick Ratio | 2.28 |
| Debt / Equity | 1.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -47.21 |
Financial Efficiency
Return on equity (ROE) is -277.74% and return on invested capital (ROIC) is -124.80%.
| Return on Equity (ROE) | -277.74% |
| Return on Assets (ROA) | -31.66% |
| Return on Invested Capital (ROIC) | -124.80% |
| Return on Capital Employed (ROCE) | -70.33% |
| Revenue Per Employee | $234,391 |
| Profits Per Employee | -$878,469 |
| Employee Count | 64 |
| Asset Turnover | 0.13 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -13.57% in the last 52 weeks. The beta is -0.12, so XLO's price volatility has been lower than the market average.
| Beta (5Y) | -0.12 |
| 52-Week Price Change | -13.57% |
| 50-Day Moving Average | 0.69 |
| 200-Day Moving Average | 0.83 |
| Relative Strength Index (RSI) | 52.72 |
| Average Volume (20 Days) | 426,402 |
Short Selling Information
The latest short interest is 4.31 million, so 8.31% of the outstanding shares have been sold short.
| Short Interest | 4.31M |
| Short Previous Month | 3.82M |
| Short % of Shares Out | 8.31% |
| Short % of Float | 18.39% |
| Short Ratio (days to cover) | 10.69 |
Income Statement
In the last 12 months, XLO had revenue of $15.00 million and -$56.22 million in losses. Loss per share was -$1.08.
| Revenue | 15.00M |
| Gross Profit | 13.02M |
| Operating Income | -56.65M |
| Pretax Income | -65.53M |
| Net Income | -56.22M |
| EBITDA | -55.02M |
| EBIT | -56.65M |
| Loss Per Share | -$1.08 |
Full Income StatementBalance Sheet
The company has $121.55 million in cash and $7.57 million in debt, giving a net cash position of $113.99 million or $2.20 per share.
| Cash & Cash Equivalents | 121.55M |
| Total Debt | 7.57M |
| Net Cash | 113.99M |
| Net Cash Per Share | $2.20 |
| Equity (Book Value) | 7.07M |
| Book Value Per Share | 0.14 |
| Working Capital | 70.46M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$13.33 million and capital expenditures -$438,000, giving a free cash flow of -$13.77 million.
| Operating Cash Flow | -13.33M |
| Capital Expenditures | -438,000 |
| Free Cash Flow | -13.77M |
| FCF Per Share | -$0.27 |
Full Cash Flow StatementMargins
| Gross Margin | 86.80% |
| Operating Margin | -377.63% |
| Pretax Margin | -374.79% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
XLO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -17.92% |
| Shareholder Yield | -17.92% |
| Earnings Yield | -154.95% |
| FCF Yield | -37.94% |
Analyst Forecast
The average price target for XLO is $3.00, which is 328.51% higher than the current price. The consensus rating is "Buy".
| Price Target | $3.00 |
| Price Target Difference | 328.51% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 9.75% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
XLO has an Altman Z-Score of -4.78 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.78 |
| Piotroski F-Score | 4 |
